Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy

References

• Rasheed S, Yan JS, Lau A, Chan AS. HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteonomics study. PLoS ONE3(8), 1–15 (2008).
   Google Scholar
• Haugaard SB, Andersen O, Dela F et al. Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic β-cells. Eur. J. Endocrinol.152, 103–112 (2005).
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med.352, 48–62 (2005).
   PubMed Web of Science ®Google Scholar
• Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J. Acquir. Immune Defic. Syndr.50, 499–505 (2009).
   PubMed Web of Science ®Google Scholar
• Wand H, Calmy A, Carey D et al. Metabolic syndrome, cardiovascular disease and Type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS21, 2445–2453 (2007).
   PubMed Web of Science ®Google Scholar
• van der Valk M, Allick G, Weverling GJ et al. Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. J. Clin. Endocrinol. Metab.89, 3554–3560 (2004).
   PubMedGoogle Scholar
• Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation119, 770–772 (2009).
   PubMedGoogle Scholar
• Hadigan C, Kamin D, Liebau J et al. depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. Am. J. Physiol. Endocrinol. Metab.290, E289–E298 (2006).
   Google Scholar
• Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin. Exp. Immunol.135, 273–279 (2004).
   PubMed Web of Science ®Google Scholar
• Jones SP, Waitt C, Sutton R, Back DJ, Pirmohamed M. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS22, 1293–1298 (2008).
   PubMedGoogle Scholar
• Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and the risk of myocardial infarction in men. JAMA291, 1730–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Duncan BD, Schmidt MI, Pankow JS et al. Adiponectin development of Type 2 diabetes. The Atherosclerosis Risk in Communities Study. Diabetes53, 2473–2478 (2004).
   PubMed Web of Science ®Google Scholar
• Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin. Infect. Dis.37(Suppl. 2), S85–S90 (2003).
   PubMed Web of Science ®Google Scholar
• Worm SW, De Wit S, Weber R et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation119, 805–811 (2009).
   PubMed Web of Science ®Google Scholar
• Kotler DP, Ionescu G, Johnson JA et al. Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin. Infect. Dis.37(Suppl. 2), S47–S51 (2003).
   PubMedGoogle Scholar
• Calza L, Manfredi R, Chiodo F. Dyslipidemia associated with antiretroviral therapy in HIV-infected patients. J. Antimicrob. Chemother.53, 10–14 (2004).
   PubMed Web of Science ®Google Scholar
• Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am. J. Ther.13, 248–260 (2006).
   PubMed Web of Science ®Google Scholar
• Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA289, 2978–2982 (2003).
   PubMed Web of Science ®Google Scholar
• Shlay JC, Visnegarwala F, Bartsch G et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J. Acquir. Immune. Defic. Syndr.38, 147–155 (2005).
   PubMed Web of Science ®Google Scholar
• Seoane E, Resino S, Micheloud D et al. Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption. J. Acquir. Immune Defic. Syndr.48, 455–459 (2008).
   PubMedGoogle Scholar
• Martin A, Mallon PWG. Therapeutic approaches to combating lipoatrophy: do they work? J. Antimicrob. Chemo.55, 612–615 (2005).
   PubMed Web of Science ®Google Scholar
• Cazanave C, Dupon M, Lavignolle-Aurillac V et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS22(3), 395–402 (2008).
   PubMedGoogle Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS20, 2165–2174 (2006).
   PubMed Web of Science ®Google Scholar
• Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large US healthcare system. J. Clin. Endocrinol. Metab.93, 3499–3504 (2008).
   PubMed Web of Science ®Google Scholar
• van Den Bout-Van Den Beukel CJP, Fievez L, Michels M et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res. Hum. Retroviruses24, 1375–1382 (2008).
   PubMed Web of Science ®Google Scholar
• Cooper DA, Bloch M, Humphries A et al. Simplification with fixed-dose tenofovir/emtricitabine or abacavir/lamivudine in adults with suppressed HIV replication: the STEAL study, a randomized, open-label, 96-week, non-inferiority trial. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, QC, Canada, 8–11 February 2009.
   Google Scholar
• Stein JH. Managing cardiovascular risk in patients with HIV infection. J. Acquir. Immune. Defic. Syndr.38, 115–123 (2005).
   PubMed Web of Science ®Google Scholar
• Sharma TS, Messiah S, Fisher S, Miller TL, Lipshultz SE. Accelerated cardiovascular disease and myocardial infarction risk in patients with the human immunodeficiency virus. J. Cardiometab. Syndr.3, 93–97 (2008).
   PubMedGoogle Scholar
• Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS22(Suppl. 3), S19–S26 (2008).
   PubMedGoogle Scholar
• Barbaro G. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection. Clin. Ter.159, 51–55 (2008).
   PubMed Web of Science ®Google Scholar
• Samaras K, Gan SK, Peake P, Carr A, Campbell LV. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity17(1), 53–59 (2009).
   PubMed Web of Science ®Google Scholar
• Fiala M, Murphy T, MacDougall J et al. HAART drugs induces mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovascular Toxicol.4, 327–337 (2005).
   Google Scholar
• Meng Q, Lima JA, Lai H et al. Coronary artery calcifications, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am. Heart J.144, 642–648 (2002).
   PubMed Web of Science ®Google Scholar
• Acevedo M, Sprecher DL, Calabrese L et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: ‘a call for prevention’. Atherosclerosis163, 349–354 (2002).
   PubMed Web of Science ®Google Scholar
• The D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med.349, 1993–2003 (2007).
   Google Scholar
• Torriani FJ, Komarow L, Parker RA et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. J. Am. Coll. Cardiol.52, 569–576 (2008).
   PubMed Web of Science ®Google Scholar
• El Sadr WM, Lundgren JD, Neaton JD et al.; Strategies for Management of Antiretroviral Therapy (SMART) study group. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med.355, 2283–2296 (2006).
   PubMed Web of Science ®Google Scholar
• Strategies for Management of Antiretroviral Therapy (SMART) study group. Risk of opportunistic disease and death after reinitiating continuous antiretroviral therapy in HIV patients previously receiving episodic therapy: a randomised trial. Ann. Intern. Med.149, 289–299 (2008).
   PubMed Web of Science ®Google Scholar
• van Vonderen MGA, Smulders YM, Stehouwer CDA et al. Carotid-intima media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J. Acquir. Immune. Defic. Syndr.50(2), 153–161 (2009).
   PubMedGoogle Scholar
• Oliviero U, Bonadies G, Apuzzi V et al. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis (2008) (Epub ahead of print).
   Google Scholar
• Mondy KE, de las Fuentes L, Waggoner A et al. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. AIDS22, 849–856 (2008).
   PubMedGoogle Scholar
• Monsuez JJ, Charniot JC, Escaut L et al. HIV-associated vascular diseases: structural and functional changes, clinical implications. Int. J. Cardiol.133(3), 293–306 (2009).
   PubMedGoogle Scholar
• Mondy KE. Determinants of endothelial function in human immunodeficiency virus infection: a complex interplay among therapy, disease, and host factors. J. Cardiometab. Syndr.3, 88–92 (2008).
   PubMedGoogle Scholar
• Law MG, Moller NF, El-Sadr et al.; the D:A:D study group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med.7, 218–230 (2006)
   PubMed Web of Science ®Google Scholar
• D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet371, 1471–1426 (2008).
   Google Scholar
• Brothers CH, Hernandez JE, Cutrell AG et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J. Acquir. Immune Defic. Syndr51(1), 20–28 (2009).
   PubMed Web of Science ®Google Scholar
• Stein JH, Currier JS. Risk of myocardial infarction and nucleoside analogues. Lancet371(9622), 1391–1392 (2008).
   PubMedGoogle Scholar
• Reiss P. Abacavir and cardiovascular risk. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, QC, Canada, 8–11 February, 2009.
   Google Scholar
• Kuller LH, Tracy R, Belloso W et al.; INSIGHT SMART study group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLos Med.5(10), E203 (2008).
   PubMed Web of Science ®Google Scholar
• Benson C, Ribaudo H, Zheng et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, QC, Canada, 8–11 February 2009.
   Google Scholar
• Lang S, Mary-Krause M, Cotte L et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, QC, Canada, 8–11 February, 2009.
   Google Scholar
• Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. J. Acquir. Immune. Defic. Syndr.39, 307–312 (2005).
   PubMed Web of Science ®Google Scholar
• Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin. Infect. Dis.46, 1101–1110 (2008).
   PubMedGoogle Scholar
• Escaut L, Monsuez JJ, Merad M et al. Coronary artery disease in HIV infected patients. Intensive Care Med.29, 969–973 (2003).
   PubMedGoogle Scholar
• Boccara F, Cohen A, Di Angelantonio E et al. Coronary artery bypass graft in HIV-infected patients: a mulitcenter case control study. Curr. HIV Res.6, 59–64 (2008).
   PubMed Web of Science ®Google Scholar
• Boccara F, Teiger E, Cohen A et al. Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. Heart92, 543–544 (2006).
   PubMedGoogle Scholar
• Hadigan C, Corcoran C, Basgoz N et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA284, 472–477 (2000).
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Carey D et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet363, 429–438 (2004).
   PubMed Web of Science ®Google Scholar
• Calvalcanti RB, Raboud J, Shen S et al. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipatrophy. J. Infect. Dis.195, 1754–1761 (2007).
   PubMedGoogle Scholar
• Bevilacqua M, Dominguez LJ, Barbagalli M. Insulin resistance and the cardiometabolic syndrome in HIV infection. J. Cardiometab. Syndr.4, 40–43 (2009).
   PubMedGoogle Scholar
• Modrich L, Scherzer R, Zolopa A et al. Factors associated with mortality in the study of fat redistribution and metabolic change in HIV infection. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, QC, Canada, 8–11 February, 2009.
   Google Scholar